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Daniel H. Shevrin, Robert Dreicer, Maha Hussain, Mario Eisenberger, Manish Kohli, Elizabeth R. Plimack,
Nicholas J. Vogelzang, Joel Picus, Matthew M. Cooney, Jorge A. Garcia, Robert S. DiPaola, and Christopher J.
Sweeney
A B S T R A C T
Purpose
Docetaxel added to androgen-deprivation therapy (ADT) significantly increases the longevity of
some patients with metastatic hormone-sensitive prostate cancer. Herein, we present the out-
comes of the CHAARTED (Chemohormonal Therapy Versus Androgen Ablation Randomized Trial for
Extensive Disease in Prostate Cancer) trial with more mature follow-up and focus on tumor volume.
Patients and Methods
In this phase III study, 790 patients with metastatic hormone-sensitive prostate cancer were equally
randomly assigned to receive either ADT in combinationwith docetaxel 75mg/m2 for up to six cycles
or ADT alone. The primary end point of the study was overall survival (OS). Additional analyses of the
prospectively defined low- and high-volume disease subgroups were performed. High-volume
disease was defined as presence of visceral metastases and/or $ four bone metastases with at
least one outside of the vertebral column and pelvis.
Results
At a median follow-up of 53.7 months, the median OS was 57.6 months for the chemohormonal
therapy arm versus 47.2months for ADT alone (hazard ratio [HR], 0.72; 95%CI, 0.59 to 0.89;P= .0018).
For patientswith high-volumedisease (n =513), themedianOSwas 51.2monthswith chemohormonal
therapy versus 34.4 months with ADT alone (HR, 0.63; 95% CI, 0.50 to 0.79; P, .001). For those with
low-volume disease (n = 277), no OS benefit was observed (HR, 1.04; 95% CI, 0.70 to 1.55; P = .86).
Conclusion
The clinical benefit from chemohormonal therapy in prolonging OS was confirmed for patients with
high-volume disease; however, for patients with low-volume disease, no OS benefit was discerned.
J Clin Oncol 36:1080-1087. © 2018 by American Society of Clinical Oncology
INTRODUCTION
Although most patients with metastatic hormone-
sensitive prostate cancer (mHSPC) initially re-
spond to androgen-deprivation therapy (ADT),1
the duration of response is variable, and invariably,
all patients develop castration-resistant prostate
cancer (CRPC). Several therapies have been shown
to improve the overall survival (OS) of men with
CRPC; however, most patients eventually die as
a result of CRPC within a few years.2 Combining
novel therapies with ADT at the time of initiating
systemic therapy for mHSPC has emerged as
a strategy to potentially delay the development of
CRPC and improve quality of life and OS.3-6
Docetaxel was the first drug shown to im-
prove the OS of men with mHSPC.3,4 Early
treatment with docetaxel is hypothesized to attack
castration-resistant clones that may already be
present at the time of presentation with metastatic
disease, a phenomenon that is probably pro-
portional to disease burden. Thus, early treatment
with cytotoxic chemotherapy may delay pro-
gression to CRPC. The first phase III study of
docetaxel with ADT versus ADTalone in mHSPC
(GETUG-AFU 15 [Groupe d’Etudes des Tumeurs
Uro-Ge´nitales and Association Française d’Ur-
ologie 15]) failed to show a survival benefit from
docetaxel,7 although with longer follow-up, there
was a nonsignificant trend in favor of the com-
bination arm (median OS of 48.6 months with
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ADT alone v 62.1 months with ADT plus docetaxel; P = .3).8
Then, the interim analysis of the CHAARTED (Chemohormonal
Therapy Versus Androgen Ablation Randomized Trial for Extensive
Disease in Prostate Cancer) trial as well as that of the STAMPEDE
(Systemic Therapy in Advancing or Metastatic Prostate Cancer:
Evaluation of Drug Efficacy) trial demonstrated a survival
benefit.3,4 One notable difference between GETUG-AFU 15
versus STAMPEDE and CHAARTED was access to newer life-
prolonging therapies for CRPC. Interestingly, the ADT alone arms
of CHAARTED and metastatic STAMPEDE cohort had a median
OS of 44 and 45 months, respectively, suggesting a similar mix
between patients with low and high tumor burden. CHAARTED
and GETUG-AFU 15 used the same definition for low- and high-
volume disease, but those with low-volume disease comprised 35%
(277 of 790) of patients in CHAARTED and 52.5% (202 of 385) of
patients in GETUG-AFU 15. The long-term follow-up of GETUG-
AFU 15 noted a trend in improvement for OS with the high-
volume subgroup, in line with STAMPEDE and CHAARTED.8,9 In
contrast, there was no suggestion of benefit from early docetaxel in
low-volume patients (hazard ratio [HR], for death, 1.02; 95% CI,
0.67 to 1.55; P = .9).8
Another variable possibly associated with poorer outcome
with ADT alone is de novo metastatic disease.10,11 Furthermore,
retrospective studies have suggested that treatment of the primary
tumor in patients with metastatic disease may confer a survival
benefit.12-15 As such, several randomized phase III trials of systemic
therapy with or without treatment of the primary tumor are under
way (ClinicalTrials.gov identifiers NCT00268476, NCT01957436,
NTR271, NCT01751438, and NCT02454543).
We previously reported a survival benefit with the addition of
docetaxel at an interim evaluation of the CHAARTED study.3 The
survival benefit was noted for the study population as a whole (HR
for death, 0.61; 95% CI, 0.47 to 0.80; P , .001), with the greatest
benefit demonstrated in the high-volume subgroup (HR for death,
0.6; 95% CI, 0.45 to 0.81; P , .001), although the study was
powered for the entire population and not the subgroups. At the
time of the first report, there were only 44 deaths among 277
patients with low-volume disease, and there was a nonsignificant
decrease in the risk of death (HR for death, 0.6; 95% CI, 0.32 to
1.13; P = .11). Here we present the updated analysis of the trial as
a whole, by disease volume as prespecified, as well as by an un-
planned analysis on the basis of prior local therapy (PLT) with or
without curative intent.
PATIENTS AND METHODS
Study Design and Participants
As detailed previously,3 this multicenter, randomized, open-label,
phase III National Cancer Institute study led by the Eastern Cooperative
Oncology Group–American College of Radiology Imaging Network en-
rolled patients with mHSPC who had performance status and organ
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Fig 1. CONSORT diagram. Overview of
screened and randomly assigned patients.
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function suitable for docetaxel. All patients provided written informed
consent before study entry. The study was conducted in accordance with
the Declaration of Helsinki for human subject protection.
Procedures
Eligible patients were randomly assigned at a one-to-one ratio to
ADTalone versus ADT plus docetaxel at a dose of 75 mg/m2 every 3 weeks
for up to six cycles without daily prednisone. Randomization was stratified
according to age (, 70 v $ 70 years), Eastern Cooperative Oncology
Group performance status (0 to 1 v 2), duration of prior adjuvant therapy
with ADT (. 12 v # 12 months), planned use of combined androgen
blockade for . 30 days (yes v no), and use of agents to prevent skeletal-
related events (eg, zoledronic acid or denosumab). A key stratification
factor was disease volume (high v low), with high-volume disease defined
as presence of visceral metastases and/or at least four bone lesions with at
least one lesion outside of the vertebral column and/or pelvis.
Neither dose modification nor intermittent ADTwas permitted. Use
of nonsteroidal antiandrogens was at the discretion of the investigators.
Patients were allowed only two dose reductions for docetaxel, the first to
65 mg/m2 and, if indicated, a second to 55 mg/m2. Patients discontinued
docetaxel permanently if there was a delay of . 3 weeks from the sched-
uled treatment day. Growth factor support was at the discretion of the
investigators.
Study Assessments
Patients receiving chemohormonal therapy were evaluated every
3 weeks for the duration of treatment with chemotherapy and every
3 months thereafter, whereas patients receiving ADT alone were evaluated
every 3 months. Radiographic disease assessment (with computed to-
mography [CT] of the abdomen and pelvis, x-ray or CT of the chest, and
bone scan) was performed at baseline, at the time of development of
CRPC, and/or as clinically indicated. For patients with measurable disease,
disease evaluation was based on Response Evaluation Criteria in Solid
Tumors (version 1.0). Serum prostate-specific antigen (PSA) concentra-
tion was checked with every visit. Complete PSA response was defined as
a decrease to , 0.2 ng/mL confirmed by a second PSA 4 weeks later.
Disease progression by PSA was defined as an increase in the PSA level
by. 50% above nadir confirmed by a consecutive increase at least 2 weeks
later. For patients with a PSA nadir of, 2 ng/mL, a PSAvalue of$ 2 ng/mL
was required for disease progression by PSA only and qualified as CRPC.
The primary end point of the study was OS, defined as time from
random assignment until death resulting from any cause. Secondary end
points included time to development of CRPC, defined either serologically
or clinically from the time of random assignment until PSA progression,
development of worsening symptoms, evidence of radiographic progression,
or patient’s deterioration as per investigator’s opinion.
Statistical Analysis
The Kaplan-Meier method16 was used to characterize event-time
distributions. Cox proportional hazards models,17 stratified on stratifi-
cation factors at random assignment, were used to estimate HRs and test
for significance for time-to-event end points.
RESULTS
Patients
Between July 2006 and December 2012, 790 eligible patients
were enrolled (Fig 1), including 397 in the ADT plus docetaxel arm
Table 1. OS and No. of Deaths by Subgroup
Subgroup
ADT Plus Docetaxel ADT Alone
HR (95% CI)* P
No. of
Patients
No. of
Deaths
Median OS
(95% CI; months)
No. of
Patients
No. of
Deaths
Median OS
(95% CI; months)
Overall 397 188 57.6 (52.0 to 63.9) 393 211 47.2 (41.8 to 52.8) 0.72 (0.59 to 0.89) .0018
High volume 263 137 51.2 (45.2 to 58.1) 250† 162 34.4 (30.1 to 42.1) 0.63 (0.50 to 0.79) , .001
Low volume 134 51 63.5 (58.3 to 78.5) 143 49 NR (59.8 to NR) 1.04 (0.70 to 1.55) .86
High volume/
de novo
214 112 48.0 (42.5 to 56.7) 207 141 33.1 (29.5 to 39.2) 0.63 (0.49 to 0.81) , .001
High volume/
prior local
therapy
49 25 66.9 (49.1 to 76.9) 42 21 51.7 (27.2 to NR) 0.72 (0.36 to 1.46) .37
Low volume/
de novo
75 33 58.3 (53.8 to 79.3) 79 34 59.8 (49.1 to NR) 0.86 (0.52 to 1.42) .55
Low volume/
prior local
therapy
59 18 69.6 (59.6 to NR) 64 15 NR (NR to NR) 1.25 (0.60 to 2.60) .55
Abbreviations: ADT: androgen-deprivation therapy; HR, hazard ratio; NR, not reached; OS, overall survival.
*Stratified on stratification factors at random assignment.
†On-study form not submitted for one patient so prior local therapy unknown.
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and 393 in the ADT alone arm. This report represents data with
a cutoff date for survival of April 23, 2016, resulting in a median
follow-up of 53.7 months. Treatment groups were well balanced, as
previously described.3 Themedian age was 64 years (range, 36 to 88
years) in the combination arm versus 63 years (range, 39 to 91
years) in the ADT alone arm. In terms of tumor volume, 263
patients (66.2%) in the combination arm and 250 patients (63.6%)
in the ADTalone arm had high-volume disease. Furthermore, 289
patients (72.8%) in the combination arm versus 286 patients
(72.8%) in the ADTalone arm had had no PLTand were considered
to have de novo metastatic disease.
Efficacy
At the time of this analysis, there were 188 deaths in the
combination arm and 211 deaths in the ADT alone arm. For
the overall population, the median OS was 10.4 months longer in
the combination arm (57.6 v 47.2 months; HR for death in the
combination arm, 0.72; 95% CI, 0.59 to 0.89; P = .0018; Table 1;
Fig 2). Longer follow-up confirmed that the effect of docetaxel
was more pronounced for patients with high-volume disease. In
this prospectively defined subgroup, with a median follow-up of
53.7 months, there was a median OS benefit of 16.8 months
(median OS, 51.2 v 34.4 months; HR for death in the combination
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arm, 0.63; 95% CI, 0.50 to 0.79; P, .001). In contrast, in the low-
volume subgroup, with a median follow-up of 53.8 months,
a survival benefit from docetaxel was not confirmed (median OS,
63.5 months for the chemohormonal arm v not reached for the
ADT alone arm; HR for death in the combination arm, 1.04; 95%
CI, 0.70 to 1.55; P = .86; Table 1; Fig 3). The interaction between
treatment and disease volume was examined and showed het-
erogeneity between patients with high- and low-volume disease
(P = .033; Fig 4). The benefit of docetaxel treatment was detected in
all other subgroups analyzed and was similar to the initial analysis
(Data Supplement).
Other clinical end points assessed were time to development of
CRPC (Table 2) and time to clinical progression (Table 3). The
time to CRPC was 19.4 months in the combination arm versus
11.7 months in the ADT alone arm (HR in the combination arm,
0.61; 95% CI, 0.52 to 0.73; P , .001). For high-volume disease, the
median time to CRPC was 14.9 months for the combination arm
versus 8.6 months for the ADTalone arm (HR for the combination
arm, 0.58; 95%CI, 0.47 to 0.71; P, .001); for low-volume disease, it
was 31.0 months for the combination arm versus 22.7 months for
the ADTalone arm (HR for the combination arm, 0.70; 95%CI, 0.50
to 0.96; P = .03). Similarly, the median time to clinical progression
was 33.0 months for the combination arm versus 19.8 months in
the ADTalone arm (HR in the combination arm, 0.62; 95% CI, 0.51
to 0.75; P , .001), a difference that was confirmed for patients
with high-volume disease (median time to clinical progression,
27.3 months for the combination arm v 13.0 months for the ADT
alone arm; HR in the combination arm, 0.53; 95% CI, 0.42 to 0.67;
P , .001) but not for those with low-volume disease (median time
to clinical progression, 42.5 months in the combination arm v
44.3 months in the ADT alone arm; HR in the combination arm,
0.86; 95% CI, 0.60 to 1.25; P = .43). An unplanned analysis of
progression-free survival defined by survival and CRPC as well as
survival and clinical progression was conducted and was consistent
with the results presented (Data Supplement).
When outcome was analyzed by type of presentation, patients
with high-volume de novo metastatic disease (n = 421) were found
to have a survival benefit of 14.9 months from addition of docetaxel
to ADT (median OS, 48.0 v 33.1 months; HR for death in the
combination arm, 0.63; 95% CI, 0.49 to 0.81; P , .001). In the
smaller subgroup of patients with high-volume disease with PLT
(n = 91), those who received ADT alone had a better outcome
compared with their counterparts with de novo metastatic disease.
When docetaxel was added, there was a numeric improvement in
OS; however, this was not statistically significant (median OS, 66.9
v 51.7 months; HR for death in the combination arm, 0.72; 95%
CI, 0.36 to 1.46; P = .37; Table 1; Fig 3). In contrast, for the low-
volume subgroups, neither patients with de novometastatic disease
nor patients with PLTwere found to derive a survival benefit from
docetaxel (de novo metastatic low-volume disease: median OS,
58.3 months for the combination arm v 59.8 months for the ADT
alone arm; HR for death in the combination arm, 0.86; 95% CI,
0.52 to 1.42; P = .55; low-volume metastatic disease with PLT:
median OS, 69.6 months for the combination arm v not reached
for the ADTalone arm; HR for death in the combination arm, 1.25;
95% CI, 0.60 to 2.60; P = .55; Table 1; Fig 3).
Safety
A summary of the adverse effects observed in the combination
arm was included in the initial publication; these were in accor-
dance with previous experience with docetaxel.9 No additional
long-term adverse effects were observed.
DISCUSSION
The updated analysis of the CHAARTED trial with a median
follow-up of 53.7 months confirms the OS benefit from early
treatment with docetaxel seen at the interim analysis with a median
follow-up of 28.9 months, which resulted in an early data release.
In addition, all the secondary end points were in favor of the
combination arm. With longer follow-up, the clinical benefit
observed with chemohormonal therapy was confirmed for patients
with high-volume disease regardless of whether they had relapsed
after PLT of the prostate with or without curative intent. In con-
trast, the subgroup with low-volume disease showed no evidence
of survival benefit when docetaxel was added (HR, 1.04 with 100
deaths), despite the early analysis showing a nonsignificant HR of
0.60 with 44 deaths.
Although prospectively defined, the subgroups were not
powered to be analyzed separately. The test for heterogeneity
supports the observation that there was a differential effect of
docetaxel in the high- and low-volume subgroups. The different
outcomes between the two subgroups (namely, longer OS with
ADT alone in the low- v high-volume subgroups and no clear
benefit with early chemotherapy for the former) can guide biologic
studies and future clinical trial design. Notably, previous studies in
mHSPC have identified higher tumor volume and presence of de
novo metastatic disease as risk factors associated with shorter OS
with ADTalone.18,19 In CHAARTED, the presence of both risk factors
was associated with a median OS of approximately 3 years with ADT
0.0 0.5
Favors ADT
plus docetaxel
Favors ADT
alone
1.0 1.5
Group
Overall
High-volume disease
Low-volume disease
No.
790
513
277
0.72
0.63
1.04
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0.59 to 0.89
0.50 to 0.79
0.70 to 1.55
95% CI
Fig 4. Test of heterogeneity between patients with
high- and low-volume disease. ADT, androgen-deprivation
therapy. The size of the squares is proportional to the
inverse of the variance of the log hazard ratio (small
squares correspond to large variances).
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alone; only one risk factor (de novo presentation or high-volume
disease) generated a median OS of approximately 5 years, and
absence of both was associated with a median OS of approximately
70 months. This was also noted in the GETUG-AFU 15 analysis.20
Moreover, the more indolent behavior of the low-volume subgroup
was associated with no clear OS benefit from early docetaxel
despite a modest delay in time to CRPC (mostly PSA rise). This is
not to say that some patients with low-volume disease, especially
those with de novo presentation, do not benefit. When studied as
a unique subgroup, although there was a suggestion of benefit for
a few patients in the early phase, there was no clear OS im-
provement for the subgroup as a whole with longer follow-up.
More precise biomarkers are urgently needed to determine the
patient phenotype that might benefit from early chemotherapy in
this setting. The findings also suggest that patients with delayed
presentation of metastatic disease and lower tumor burden probably
have a distinct underlying biology and thus may have a differential
response to a given treatment. For example, patients with late relapse
and low tumor burden may benefit from more intense androgen
receptor (AR) pathway inhibition. In contrast, these data indicate that
patients with a higher disease volume are more likely to benefit from
early docetaxel with ADT than patients with a lower tumor burden.
The benefit from early docetaxel in terms of delay to CRPC
and subsequent clinical progression was more pronounced in the
high-volume subgroup than in the low-volume subgroup. This
suggests that there is a greater effect of secondary therapies for
CRPC after early docetaxel, and this may contribute to the OS
benefit in high-volume disease and may explain why no clear
benefit was seen in GETUG-AFU 15, where there was less access to
newer therapies for CRPC during the study conduct. In contrast,
sequential therapies after ADT alone seem more effective as
salvage treatments for patients with low-volume disease. This
observation leads to the hypothesis that greater tumor debulking
and attacking of AR-driven and AR-independent disease with
upfront chemothormonal therapy in patients with greater tumor
burden at baseline facilitate the greater benefit derived from the
agents shown to prolong OS in the CRPC setting. Efforts are
planned to more accurately capture treatment response to sub-
sequent therapies in CHAARTED.
Despite the limitations of subgroup analyses, the information
derived can inform future trial design in terms of projections for
outcomes to determine sample size, especially for oligometastatic
disease. Moreover, the use of conventional CT and technetium
bone scan imaging, although crude, provides a cut point that
identifies patients who benefit from early docetaxel and can serve as
a benchmark for future molecular and radiologic biomarker work.
This knowledge can also help inform retrospective studies, such as
whether treatment of the primary tumor in de novo metastatic
disease is associated with better outcomes because patients with
lower burden of disease may have been selected for treatment of the
primary tumor.
Finally, these results need to be interpreted in light of the
recent data demonstrating a significant benefit from the addition of
abiraterone to ADT to the same degree as docetaxel in high-volume
disease (OS, not reached v 34.7 months; HR, 0.62; 95% CI, 0.51 to
0.76; P , .001 and progression-free survival, 33 v 14.8 months;
HR, 0.47; 95% CI, 0.39 to 0.55; P , .001 [both in favor of the
abiraterone plus ADTarm in the LATITUDE study]; HR for death,
0.63; 95% CI, 0.52 to 0.76; P , .001 and HR for treatment failure
events, 0.29; 95% CI, 0.25 to 0.34; P , .001 [both in favor of the
abiraterone plus ADT arm in the STAMPEDE trial]).5,6 Notably,
the predominant population accrued to these studies had de novo
metastatic disease. The future question will be whether to add
docetaxel to ADT and newer AR-targeting agents such abiraterone
(or enzalutamide if proven to confer OS benefit in the mHSPC
setting). Fortunately, three studies have or have nearly completed
accrual and are stratified by docetaxel use and will allow an analysis
of ADT plus docetaxel with or without abiraterone, enzalutamide,
Table 3. Time to Clinical Progression
Subgroup
ADT Plus Docetaxel ADT Alone
HR (95% CI)* PNo. of Patients No. of PDs
Median
(95% CI; months) No. of Patients No. of PDs
Median
(95% CI; months)
Overall 397 194 33.0 (29.1 to 40.9) 393 242 19.8 (17.8 to 22.5) 0.62 (0.51 to 0.75) , .001
High volume 263 142 27.3 (21.9 to 32.7) 250 176 13.0 (11.1 to 17.2) 0.53 (0.42 to 0.67) , .001
Low volume 134 52 42.5 (34.0 to NR) 143 66 44.3 (28.9 to 66.5) 0.86 (0.60 to 1.25) .43
Abbreviations: ADT, androgen-deprivation therapy; HR, hazard ratio; NR, not reached; PD, disease progression.
*Stratified on stratification factors at random assignment.
Table 2. Time to CRPC (PSA rise or clinical progression)
Subgroup
ADT Plus Docetaxel ADT Alone
HR (95% CI)* PNo. of Patients No. of CRPCs
Median Time
(95% CI; months)
No. of
Patients No. of CRPCs
Median Time
(95% CI; months)
Overall 397 257 19.4 (16.8 to 22.6) 393 303 11.7 (10.8 to 14.4) 0.61 (0.52 to 0.73) , .001
High volume 263 190 14.9 (12.4 to 17.2) 250 213 8.6 (6.8 to 10.5) 0.58 (0.47 to 0.71) , .001
Low volume 134 67 31.0 (23.1 to 51.1) 143 90 22.7 (18.9 to 29.1) 0.70 (0.50 to 0.96) .03
Abbreviations: ADT, androgen-deprivation therapy; CRPC, castration-resistant prostate cancer; HR, hazard ratio; PSA, prostate-specific antigen.
*Stratified on stratification factors at random assignment.
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or apalutamide (ClinicalTrials.gov identifiers NCT02446405,
NCT01957436, and NCT02489318).
In conclusion, the updated data confirm the benefit of
docetaxel in combination with ADT for patients with mHSPC,
which is clearly defined for patients with high-volume disease.
Although burden of metastases determined by conventional im-
aging can assist in patient selection for treatment with docetaxel,
additional studies should focus on identifying more accurate
biomarkers and gaining a better understanding of the underlying
mechanisms of resistance to ADT and the biologic basis for AR
targeting and cytotoxics in prostate cancer.21-23
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